The WHO selects Tivanisiran as the international nonproprietary name for SYL1001
Sylentis, a Pharmaceutical Company of PharmaMar Group (MCE: PHM), pioneer in the development of new compounds based on genetic silencing technology through RNA interference (RNAi),...





